Drug class
Antiviral; nucleoside analogue prodrug targeting SARS-CoV-2 RNA polymerase
Mechanism of action
A prodrug converted intracellularly to N-hydroxycytidine triphosphate, which is incorporated by viral RNA-dependent RNA polymerase and causes accumulation of errors in the viral genome (viral error induction or lethal mutagenesis).
General use cases
- Treatment of mild-to-moderate COVID-19 in adults at increased risk of progression when alternative authorised treatment options are not appropriate, subject to current local authorisation and product-label criteria.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
